Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine.

AIDS Res Hum Retroviruses. 1998 Sep 20;14(14):1253-62. Unique Identifier : AIDSLINE MED/98435938
Robinson JE; Cole KS; Elliott DH; Lam H; Amedee AM; Means R; Desrosiers RC; Clements J; Montelaro RC; Murphey-Corb M; Department of Pediatrics, Tulane University Medical School, New; Orleans, Louisiana 70112, USA.

Abstract: Five rhesus monoclonal antibodies (RhMAbs) were produced by rhesus EBV transformation of peripheral blood B cells from a rhesus macaque that had been asymptomatically infected with an attenuated, macrophage-tropic SIV strain, 17E-Cl. These MAbs recognized conformation-dependent epitopes on SIV gp120 and could not be mapped using synthetic peptides. All five RhMAbs were able to neutralize the vaccine strain and a heterologous isolate, SIV/DeltaB670. The RhMAbs did not cross-react with HIV-2; by contrast, four human MAbs derived from an HIV-2-infected person were broadly cross-reactive with both SIV and HIV-2 gp120s. Cross-competition analysis indicated that the five RhMAbs could be placed in two groups recognizing two nonoverlapping epitopes; while the HMAbs were placed in two additional competition groups. Binding of the three group I RhMAbs (1.7F, 3.11B, and 1.10A) as well as HMAb 17A was shown to be sensitive to specific amino acid alterations in V4 occurring in natural env variants. The results of this study demonstrate that RhEBV transformation provides a means to probe rhesus antibody responses to SIV infection at the monoclonal level. RhMAbs will allow structural and functional studies of envelope glycoprotein determinants that elicit protective immune responses against SIV.

Keywords: JOURNAL ARTICLE Amino Acid Sequence Animal Antibodies, Monoclonal/BIOSYNTHESIS/*IMMUNOLOGY Base Sequence Binding, Competitive Blotting, Western Cross Reactions Fluorescent Antibody Technique Human HIV Envelope Protein gp120/IMMUNOLOGY HIV-2/IMMUNOLOGY Immunoenzyme Techniques Macaca mulatta/*IMMUNOLOGY Molecular Sequence Data Neutralization Tests Peptide Mapping Support, U.S. Gov't, P.H.S. SAIDS Vaccines/ADMINISTRATION & DOSAGE/*IMMUNOLOGY SIV/GENETICS/*IMMUNOLOGY Vaccines, Attenuated/ADMINISTRATION & DOSAGE/*IMMUNOLOGY
990228
A9920908

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .